Here’s what you should know:
1. Takeda increased revenues 3.6 percent year-over-year.
2. Takeda’s gastroenterology division was its second strongest, with revenue increasing 24.8 percent year-over-year. Entyvio and Takecab led the growth.
3. Takeda’s U.S.-based revenue increased 16.7 percent year-over-year.
4. Takeda’s CEO Christophe Weber said in a release, “Our growth drivers continued to deliver robust double-digit revenue growth, which together with our cost management initiatives led to a significant margin expansion. … Although we expect headwinds in the second half of the year, we are still confident to raise our outlook for the full year as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability.”
5. Concerning end-of-year outlooks, Takeda expects earnings of $1.720 trillion yen ($15.07 billion).
More articles on gastroenterology:
GI leader to know: Dr. Christie Choi of Texas Digestive Disease Consultants
8 GI centers to know for October
Stock market week-in-review for 5 large GI companies — Oct. 23-27
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.